Recently, the Department of Cardiovascular Medicine of the First Hospital of Harbin Medical University once again successfully performed pulmonary artery denervation for a patient with pulmonary hypertension. So far, since the Department of Cardiology of the First Hospital of Harbin Medical University successfully completed the first case of pulmonary artery denervation in Heilongjiang Province in December 2023, 8 cases of this type of surgery have been completed, with the largest number of selected cases in the province and the most experienced team surgery.
Pulmonary artery denervation (PADN) is a percutaneous pulmonary intervention technology developed by the team of Professor Chen Shaoliang from Nanjing First Hospital of Nanjing Medical University, which uses a specific catheter to deliver radiofrequency energy to the lungs
The sympathetic nerve of the adventitia arterial membrane is used to make the nerve myelin sheath disappear and the axons fuse with a high temperature of 45°C-55°C, thereby inhibiting sympathetic nerve activity, increasing cardiac output, reducing pulmonary artery pressure, inhibiting pathological remodeling of pulmonary arteries, improving patients' exercise tolerance and cardiac function, and then achieving the effect of long-term benefits of a minimally invasive surgery, which brings hope for the treatment of patients with pulmonary hypertension caused by left heart disease.
According to Professor Wang Zhaojun, pulmonary hypertension is divided into 5 types, and the treatment regimen for pulmonary hypertension caused by different causes is different. Although the prognosis of patients with type 1 pulmonary hypertension has been significantly improved with the application of targeted drugs, at present, targeted drugs only target type 1 pulmonary hypertension, and there is still no effective treatment for type 2 to 5 pulmonary hypertension.
Ms. Tong (pseudonym), a 58-year-old patient, suffered from pulmonary hypertension and heart failure for many years, accompanied by symptoms of fatigue, dyspnea, and reduced activity tolerance, which seriously affected her daily life.
After preoperative preparation, Professor Wang Zhaojun from the Department of Cardiology of the First Hospital of Harbin Medical University performed right heart catheterization (RHC) on the patient, and the results showed that the mean pulmonary artery pressure (MPAP) was 47mmHg and the pulmonary artery wedge pressure (PAWP) was 23mmHg, which clearly diagnosed pulmonary hypertension caused by left heart disease and was suitable for pulmonary artery denervation (PADN) treatment. Immediately after the operation, the mean pulmonary artery pressure (MPAP) was reduced to 42mmHg, and the pulmonary artery wedge pressure (PAWP) was reduced to 19mmHg, and the operation was successfully completed in only 50 minutes.
Ms. Tong's activity tolerance was significantly improved after surgery, and all indicators were good. This operation fully demonstrates the profound strength and level of the team of the First Hospital of Harbin Medical University in the treatment of pulmonary hypertension, confirms the safety and effectiveness of the mainland's original PADN technology, and opens a new path for the treatment of patients with pulmonary hypertension.
Zhang Haoruo